FDA Clears Biosyngen's CAR-T Therapy BRG01 for Pivotal Trial in EBV-Positive ...

Retrieved on: 2024-08-13 23:14:36

Tags for this article:

Infectious causes of cancer

Lymphoma

Orphan drugs

Post-transplant lymphoproliferative disorder

Transplantation medicine

Epstein–Barr virus

Nasopharyngeal carcinoma

Tabelecleucel

Head and neck cancer

Epstein–Barr virus infection

Epstein–Barr virus-associated lymphoproliferative diseases

Click the tags to see associated articles and topics

FDA Clears Biosyngen's CAR-T Therapy BRG01 for Pivotal Trial in EBV-Positive .... View article details on hiswai:

Excerpt

BRG01 is the first cell therapy to move into a phase 2 clinical trial for relapsed/metastatic EBV-positive nasopharyngeal carcinoma in both the US ...

Article found on: www.cgtlive.com

View Original Article